Building A Biotech Hub with Intellia Therapeutics' John Leonard, M.D.

Business Of Biotech

A tartalmat a Matt Pillar biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a Matt Pillar vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.

10M ago 55:03

MP3•Epizód kép

We love to hear from our listeners. Send us a message.

We spend a lot of time talking with our guests about building biotech companies. That’s true of this episode too, but today we’re taking a step further with John Leonard, M.D., longtime CEO at Intellia Therapeutics. In addition to how he’s built late-clinical stage Intellia, Dr. Leonard shares the foundational elements of a biotech community, particularly around rapidly-advancing technologies such as CRISPR, and what biotech ecosystems offer emerging biotechs in terms of resources, intellectual property, and support. Turns out that despite his proximity, Boston isn’t the prerequisite it used to be. This is an instructive conversation with an industry vet who’s happy to share the wealth of his knowledge.

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

Fejezetek

1. Building Successful Biotech (00:00:00)

2. CRISPR's Importance in Biotech Hubs (00:10:29)

3. The Challenges of Biotech Funding (00:24:07)

4. Biotech Community's Budgeting, Collaboration, Growth (00:40:04)

226 epizódok

#Science #MBA #Biology #Business #Matt Pillar #Biopharmaceutical #Bioprocess #Biopharma #Medicine #Therapy #Startup #Venturecapital #Entrepreneur #Pharma #Biotech